Ex vivo IFNg Enzyme-Linked ImmunoSpot (ELISpot) testing the reactivity of PBMCs to autologous tumor showed a tendency of increased reactivity in some patients (101.03, 101.04, 101.06, 101.12, and 101.15) after TIL infusion (Figure S5B), but no significant changes were detected. Here, IFNG is linked to neoplasm.